← All alumni news

STENTiT Enrolls First Patient in Clinical Trial Evaluating a Novel Stent with Regenerative Properties to Support Limb Preservation

DateJune 26, 2025
CategoriesAlumni News
STENTiT logo

EINDHOVEN, The Netherlands – June 26, 2025 – STENTiT, a pioneering medical device company, developing a novel class of stents with regenerative properties, today announced the successful implantation of its Resorbable Fibrillated Scaffold (RFS). As part of the VITAL-IT 1 study, patients with chronic limb-threatening ischemia (CLTI) below-the-knee, have successfully been treated using the RFS implant. In this clinical procedure, revascularization was achieved using an endovascular approach to restore the blood flow to the foot STENTiT’s RFS device is a bioresorbable stent built from microfibers, providing structural support to instantly open, and facilitate the reconstruction of the artery. Due to the porous design of the implant, patient’s own cells infiltrate into the mesh, triggering the formation of new vascular tissue. While the artery is being reconstructed from the inside-out, the synthetic implant gradually resorbs and ultimately disappears over time.

Read More

Share Link :